GlassScriptPhysician profile
Thomas G Sternberg
NPI 1467448175
$16,953.19
in general payments reported to CMS, 2019-2025
40 companies · $4,990 in 2025
The $4,990 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $640 · 2021: $3,206 · 2022: $1,583 · 2023: $3,052 · 2024: $2,277 · 2025: $4,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,140 · Consulting Fee: $2,738 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,220 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,139.57 |
| Consulting Fee | $2,738.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,220.00 |
| Education | $222.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,719.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $2,239.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,921.66 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $1,419.02 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Cycle Pharmaceuticals INC | $1,296.22 | 2023-2025 | Sajazir |
| Regeneron Healthcare Solutions, INC. | $853.74 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $679.22 | 2019-2025 | Ruconest |
| Csl Behring | $673.93 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Teva Pharmaceuticals USA, INC. | $594.84 | 2020-2025 | Albuterol Sulfate, Airduo Digihaler |
| Genzyme Corporation | $570.87 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $338.82 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $285.18 | 2021-2025 | Panzyga, Cutaquig |
| Genentech USA, INC. | $246.41 | 2020-2025 | Xolair |
| Pfizer INC. | $237.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.35 | 2019-2023 | Spiriva Respimat |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $174.06 | 2024-2025 | Xolair |
| Grifols USA, LLC | $166.04 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $144.87 | 2019-2023 | Auvi-Q |
| Amgen INC. | $126.71 | 2023-2025 | Tezspire, Actimmune |
| Biocryst Pharmaceuticals, INC. | $123.06 | 2022 | |
| Alk-Abello, INC | $108.39 | 2019-2022 | |
| Horizon Therapeutics Plc | $102.81 | 2020-2022 | |
| Regeneron Pharmaceuticals, INC. | $102.50 | 2025 | Dupixent |
| Blueprint Medicines Corporation | $86.21 | 2023-2025 | Ayvakit |
| Optinose US, INC. | $80.84 | 2021-2022 | |
| Abbvie INC. | $75.63 | 2022-2024 | Rinvoq |
| Shire North American Group INC | $73.01 | 2019 | |
| Lilly USA, LLC | $56.79 | 2024-2025 | Ebglyss |
| Incyte Corporation | $41.04 | 2021-2022 | |
| Mylan Specialty L.P. | $35.49 | 2022-2023 | Yupelri |
| Aimmune Therapeutics, INC. | $29.09 | 2021-2022 | |
| Phadia US INC. | $28.09 | 2023 | Immunocap |
| Verona Pharma, INC. | $22.58 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $18.69 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $16.84 | 2023 | Ryaltris |
| Leo Pharma INC. | $16.67 | 2022 | |
| Bio Products Laboratory USA, INC. | $15.94 | 2022 | |
| Adma Biomanufacturing LLC | $15.43 | 2021 | |
| Viatris Specialty LLC | $14.30 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sternberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.